Rein Therapeutics Inc. (RNTX)

Market Cap	49.83M
Revenue (ttm)	n/a
Net Income (ttm)	-29.24M
Shares Out	21.67M
EPS (ttm)	-2.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,216
Open	2.300
Previous Close	2.300
Day's Range	2.300 - 2.400
52-Week Range	1.610 - 7.420
Beta	2.23
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About RNTX

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes pre...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: RNTX
• Website: https://www.reintx.com